Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FLGT 
Fulgent Genetics Inc (FLGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/11/2025: FLGT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.18% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 02/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 534.29M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 236596 | Beta 1.54 | 52 Weeks Range 14.57 - 25.11 | Updated Date 04/2/2025 |
52 Weeks Range 14.57 - 25.11 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.07% | Operating Margin (TTM) -21.17% |
Management Effectiveness
Return on Assets (TTM) -3.76% | Return on Equity (TTM) -3.87% |
Valuation
Trailing PE - | Forward PE 7.94 | Enterprise Value 284647786 | Price to Sales(TTM) 1.88 |
Enterprise Value 284647786 | Price to Sales(TTM) 1.88 | ||
Enterprise Value to Revenue 0.96 | Enterprise Value to EBITDA -4.34 | Shares Outstanding 30865700 | Shares Floating 18678333 |
Shares Outstanding 30865700 | Shares Floating 18678333 | ||
Percent Insiders 32.76 | Percent Institutions 56.48 |
Analyst Ratings
Rating 3.33 | Target Price 27.67 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Fulgent Genetics Inc
Company Overview
History and Background
Fulgent Genetics Inc. was founded in 2011. It initially focused on providing comprehensive genomic testing services. Over time, it has expanded its offerings and reach through technological advancements and strategic partnerships, becoming a significant player in the genetic testing market.
Core Business Areas
- Genetic Testing Services: Offers a wide range of genetic tests covering various medical conditions and disease areas. Includes comprehensive panels and single-gene tests to support physicians in diagnosis and treatment decisions.
- COVID-19 Testing: During the pandemic, Fulgent provided COVID-19 testing services, which significantly boosted its revenue. Although the pandemic has ended the company still offers covid testing services.
- Biopharma Services: Provides genetic testing and related services to pharmaceutical and biotechnology companies to support drug development, clinical trials, and companion diagnostics.
Leadership and Structure
The leadership team is led by Ming Hsieh, Chairman and CEO. The organizational structure involves departments focused on R&D, sales and marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Next Generation Sequencing (NGS) Panels: Comprehensive panels targeting specific disease areas like oncology, cardiology, and neurology. Fulgent's focus on customizable panels provides flexibility for clinicians. Revenue is highly variable and depends on testing volumes. Competitors include Invitae (NVTA), Myriad Genetics (MYGN), and Genomic Health. Market share information unavailable but estimate to be small in the overall market.
- COVID-19 Testing (PCR): Fulgent offered PCR-based COVID-19 testing with fast turnaround times. Although it drove revenues during pandemic, now the competition in the market is very high and revenues are falling from this offering. Competitors include Quest Diagnostics (DGX) and LabCorp (LH).
- Companion Diagnostics Development: Partnerships with pharmaceutical companies to develop and commercialize companion diagnostics. This space is growing and has a lot of potential. Competitors include Qiagen (QGEN) and Roche (RHHBY).
Market Dynamics
Industry Overview
The genetic testing industry is experiencing rapid growth due to technological advancements, increased awareness, and expanding applications in healthcare. Personalized medicine and preventive care are driving demand.
Positioning
Fulgent Genetics is positioned as a provider of comprehensive and flexible genetic testing solutions. Its competitive advantage lies in its technological platform, customization capabilities, and competitive pricing.
Total Addressable Market (TAM)
The global genetic testing market is expected to reach hundreds of billions of dollars in the next few years. Fulgent Genetics is well-positioned to capture a significant share of this market through its diverse product portfolio and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Comprehensive test menu
- Flexible and customizable solutions
- Advanced technology platform
- Competitive pricing
- Strong relationships with biopharma companies
Weaknesses
- Reliance on COVID-19 testing revenue (decreasing)
- Relatively smaller market share compared to established players
- Customer concentration
- Dependence on third-party payers
Opportunities
- Expansion into new geographic markets
- Development of novel genetic tests
- Strategic partnerships and acquisitions
- Growing demand for personalized medicine
- Increase Biopharma test numbers
Threats
- Increased competition
- Changes in reimbursement policies
- Technological obsolescence
- Regulatory hurdles
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- NVTA
- DGX
- LH
- ILMN
Competitive Landscape
Fulgent Genetics is a smaller player compared to established diagnostic companies like Quest and LabCorp. Its advantages lie in its flexible platform and focus on customization, but it faces competition from larger companies with greater resources and brand recognition.
Major Acquisitions
Inform Diagnostics
- Year: 2022
- Acquisition Price (USD millions): 170
- Strategic Rationale: Expanding Fulgent's oncology testing capabilities and customer base.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been uneven due to reliance on COVID-19 testing. Without Covid-19 revenue the growth has been difficult
Future Projections: Future projections depend on expanding the core genetic testing business and securing new biopharma partnerships. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include expanding test offerings, investing in automation, and pursuing strategic collaborations.
Summary
Fulgent Genetics had huge gains during the COVID-19 pandemic with the huge boom in COVID testing. Now that the pandemic is over, it is working to re-establish itself in the genetic testing market. It has a strong cash position to expand its offerings and acquire new businesses. It should focus on growing its core business and securing biopharma partnerships to ensure long-term sustainable growth and offset the COVID-19 testing revenue losses.
Similar Companies
DGX
Quest Diagnostics Incorporated
DGX
Quest Diagnostics Incorporated
ILMN
Illumina Inc
ILMN
Illumina Inc
LH
Laboratory Corporation of America Holdings
LH
Laboratory Corporation of America Holdings
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications
Disclaimers:
This analysis is based on available data and estimates and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fulgent Genetics Inc
Exchange NASDAQ | Headquaters El Monte, CA, United States | ||
IPO Launch date 2016-09-29 | Chairman & CEO Mr. Ming Hsieh | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1313 | Website https://www.fulgentgenetics.com |
Full time employees 1313 | Website https://www.fulgentgenetics.com | ||
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.